5.40
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Medicinova Inc | MNOV | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.00 | 0.0% | 5.40 | 04:00:00 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 5.40 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 4.41 | 6.09 | 1.68 | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 5.40 | USD |
Medicinova Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 239.61M | 44.37M | 41.32M | $ - | $ - | -0.29 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Medicinova News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNOV Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.34 | 5.45 | 5.0543 | 5.35 | 176,502 | 0.06 | 1.12% |
| 1 Month | 6.66 | 6.76 | 4.631 | 5.73 | 1,094,818 | -1.26 | -18.92% |
| 3 Months | 6.81 | 9.65 | 4.631 | 5.87 | 609,855 | -1.41 | -20.7% |
| 6 Months | 5.05 | 13.25 | 4.631 | 9.14 | 1,023,353 | 0.35 | 6.93% |
| 1 Year | 8.00 | 13.25 | 2.79 | 8.75 | 581,257 | -2.60 | -32.5% |
| 3 Years | 6.23 | 14.50 | 2.79 | 9.05 | 284,024 | -0.83 | -13.32% |
| 5 Years | 2.78 | 14.50 | 2.622 | 8.60 | 205,634 | 2.62 | 94.24% |
Medicinova Description
| MediciNova Inc is a biopharmaceutical company. It acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of small molecule therapeutics segment. |
